Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.18 +0.17 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
5 Stocks That Moved the Market in January
These stocks illustrate the most important trends in the stock market right now. 
Via The Motley Fool
The 3 Most Undervalued Growth Stocks for Your February Buy List
These undervalued growth stocks have the value and projected growth that investors seek when researching their next investment decisions. 
Via InvestorPlace
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
Barron's Top Weekend Stock Picks: Apple, Disney, Pfizer And Tesla's Price Cuts Are Leading To Growth
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read. 
Via Benzinga
Pfizer's Sales Could Sink 33% in 2023. Here's Why to Buy the Stock Anyway.
There's a bigger story for Pfizer than its declining COVID-19 revenue. 
Via The Motley Fool
Pfizer (PFE) Q4 2022 Earnings Call Transcript
PFE earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Pfizer Beats Q4 Earnings, Issues Underwhelming 2023 Guidance
 
Via Benzinga
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Biosimilars Market 2023 Industry Size, Share, Growth and Analysis by Demand, Opportunity, Key Players, Regional Development and Forecast 2029
Biosimilars Market Size, Share and Forecast 2023-2029 Key Players are – Samsung Biologics, Intas Pharmaceuticals Ltd, Celltrion, Reliance Life Sciences, Pfizer, Coherus BioSciences, Amgen, Biocon Ltd 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Is It Time to Buy the S&P 500's 3 Worst-Performing January Stocks?
It's safe to go bargain-hunting again. Just make sure the bargain is a stock you actually want to own for the long haul. 
Via The Motley Fool
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
Can gains in Tesla, Zoom, Exact Sciences, and other growth stocks set the stage for Cathie Woods' Ark Innovation Fund to stage a comeback in 2023? 
Via MarketBeat
Topics ETFs
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Got $1,000? 3 Cheap Stocks To Buy Right Now
We may be entering a period of prolonged leadership from undervalued stocks, with these tickers poised to lead the charge. 
Via The Motley Fool
This Low-Risk ETF Can Turn $39,000 Into $1 Million in 25 Years
Funneling money into this fund can drastically simplify your investing strategy. 
Via The Motley Fool
Novavax Shares Jumped in January While Others Slipped
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line. 
Via MarketBeat
Exposures COVID-19 Product Safety
AMD To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Wednesday
Credit Suisse boosted the price target for Mondelez International, Inc. (NASDAQ: MDLZ) from $70 to $76. Credit Suisse analyst Robert Moskow maintained an Outperform rating. Mondelez shares rose 1.8% to... 
Via Benzinga
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Pfizer stock is bouncing up and down after mixed Q4 earnings. There's been an emotional battle between bulls and bears but it's time for both to get rational 
Via MarketBeat
S&P 500 Jumps 1.5%, Market Volatility Decreases
US stocks closed higher on Tuesday following the release of several earnings reports. 
Via Benzinga
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Novavax shares sank 93% last year. 
Via The Motley Fool
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.63% to 33,931.13 while the NASDAQ rose 1.20% to 11,529.99. The S&P... 
Via Benzinga
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Amgen launched its biosimilar knockoff on Tuesday at a steep discount. 
Via Investor's Business Daily
Waiting for Powell: As Fed Meeting Starts, Investors Parse Mixed Q4 Earnings and Consider What's Next for Rates
(Tuesday Market Open) With three major central banks releasing rate decisions starting tomorrow, investors might be wise to expect subdued trading Tuesday following a sell-off to start the week.  
Via Benzinga
Sony Scales Back PlayStation VR2 Output, Sam Bankman-Fried Attempted To Regain Control Of FTX, White House Plans To End COVID-19 Emergency: Today's Top Stories
Bloomberg 
Via Benzinga
Why BioNTech And Moderna Shares Are Falling After Pfizer News
BioNTech SE - ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday morning in sympathy with Pfizer Inc. (NYSE: 
Via Benzinga
Most Important Week Of Earnings Season Is Here — Will S&P 500 Companies Continue Beating Wall Street Estimates?
Earnings season is in full swing, with 35% of companies in the S&P 500 reporting this week. Company performance through the fourth quarter of 2022 will lend a clearer view into the general state of the... 
Via Benzinga
Pfizer Q4 Earnings And Revenues Beat Estimates
Pfizer came out with quarterly earnings of $1.14 per share. 
Via Talk Markets
The Expected Covid Cliff Is Here For Pfizer — Company Calls For Steep 2023 Declines
Pfizer called for steep declines in 2023 sales and earnings as Covid sales diminish. 
Via Investor's Business Daily
Biden Administration Plans To End COVID-19 Public Health Emergency In May
 
Via Benzinga
4 Discounted Dividend Stocks To Buy In February 2023
All four of these Dividend stocks pay a safe and growing dividend 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.